301. 黄斑ジストロフィー Disease details / Clinical trials / Drug dev / DR info

臨床試験数 : 59 / 薬物数 : 42 - (DrugBank : 14) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 72

薬物、開発者（Primary Sponsor）、臨床試験情報（症例登録開始年（Enrollment year）、フェーズ、ID、実施国）
4-methylpyrazole
   University of Utah
      2005   Phase 1   NCT00346853   United States
ACDN-01
   Ascidian Therapeutics, Inc
      2024   Phase 1/Phase 2   NCT06467344   United States
ACU-4429
   Acucela Inc.
      2019   Phase 3   EUCTR2018-003498-82-NL   Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003498-82-IT   Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003498-82-GB   Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003498-82-ES   Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003498-82-DK   Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2018-003498-82-FR   Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2018-003498-82-DE   Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States
ALK-001
   Alkeus Pharmaceuticals, Inc.
      2019   Phase 2   NCT04239625   United States
      2015   Phase 2   NCT02402660   United States
      2014   Phase 1   NCT02230228   -
ARC1905
   IVERIC bio, Inc.
      2018   Phase 2   EUCTR2017-004783-35-IT   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
ARC1905 20 MG/ML
   IVERIC bio
      2018   Phase 2   EUCTR2017-004783-35-HU   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004783-35-GB   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004783-35-DE   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
   OPHTHOTECH CORPORATION
      2018   Phase 2   EUCTR2017-004783-35-ES   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
Avacincaptad pegol
   Astellas Pharma Global Development, Inc.
      2018   Phase 2   NCT03364153   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
   IVERIC bio
      2018   Phase 2   EUCTR2017-004783-35-HU   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004783-35-GB   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004783-35-DE   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
   IVERIC bio, Inc.
      2018   Phase 2   EUCTR2017-004783-35-IT   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
   OPHTHOTECH CORPORATION
      2018   Phase 2   EUCTR2017-004783-35-ES   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
Blood and/or skin biopsy
   University Hospital, Lille
      2021   -   NCT04658251   France
Docosahexaenoic acid (DHA) dietary supplement
   National Eye Institute (NEI)
      2003   Phase 1   NCT00060749   United States
Emixustat
   Kubota Vision Inc.
      2017   Phase 2   NCT03033108   United States
Emixustat hydrochloride
   Acucela Inc.
      2019   Phase 3   EUCTR2018-003498-82-NL   Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003498-82-IT   Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003498-82-GB   Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003498-82-ES   Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003498-82-DK   Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2018-003498-82-FR   Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2018-003498-82-DE   Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States
Gene therapy product-MCO-010
   Nanoscope Therapeutics Inc.
      2023   -   NCT06048185   United States
Gene therapy-VMCO-010
   Nanoscope Therapeutics Inc.
      2022   Phase 2   NCT05417126   United States
HESC-RPE
   Astellas Institute for Regenerative Medicine
      2013   -   NCT02941991   United Kingdom
Interferon gamma-1B
   National Eye Institute (NEI)
      2015   Phase 1/Phase 2   NCT02338973   United States
JWK006
   West China Hospital
      2023   Phase 1/Phase 2   NCT06300476   China
LBS-008, BPN-14967
   Belite Bio, Inc
      2022   Phase 3   EUCTR2021-003253-36-DE   Australia;Belgium;China;France;Germany;Hong Kong;Korea, Republic of;Netherlands;Switzerland;Taiwan;United Kingdom;United States
      -   Phase 3   EUCTR2021-003253-36-FR   Australia;Belgium;China;France;Germany;Hong Kong;Switzerland;Taiwan;United Kingdom;United States
Lentiviral vector containing ABCA4 gene
   Oxford BioMedica (UK) Ltd
      2011   Phase 1;Phase 2   EUCTR2010-023111-34-FR   France;Italy;Netherlands
   sanofi-aventis recherche et développement
      2016   -   EUCTR2010-023111-34-NL   France;Italy;Netherlands;United States
Lentiviral vector containing THE ABCA4 gene
   sanofi-aventis recherche et développement
      2012   Phase 1;Phase 2   EUCTR2012-001990-95-FR   France;United States
Long term follow UP IN ALL patients WHO received SAR422459 IN previous study TDU13583
   Sanofi
      2012   Phase 1/Phase 2   NCT01736592   France;United States
MA09-hrpe
   Astellas Institute for Regenerative Medicine
      2012   -   NCT02445612   United States
      2011   Phase 1/Phase 2   NCT01469832   United Kingdom
      2011   Phase 1/Phase 2   NCT01345006   United States
   CHABiotech CO., Ltd
      2012   Phase 1   NCT01625559   Korea, Republic of
Madeos
   Ophthalmos Research and Education Institute
      2019   -   NCT03297515   France;Germany;Italy
Metformin hydrochloride
   National Eye Institute (NEI)
      2020   Phase 1/Phase 2   NCT04545736   United States
OCU410ST
   Ocugen
      2023   Phase 1/Phase 2   NCT05956626   United States
OPCT-001
   BlueRock Therapeutics
      2025   Phase 1/Phase 2   NCT06789445   United States
Oral disulfiram
   University of Rochester
      2025   Phase 1   NCT06319872   United States
Over THE counter DHA/EPA dietary supplementation
   University of Utah
      2007   -   NCT00420602   United States
Ranibizumab
   Manhattan Eye, Ear & Throat Hospital
      2007   Phase 1/Phase 2   NCT00470977   United States
Saffron supplementation
   Catholic University of the Sacred Heart
      2011   Phase 1/Phase 2   NCT01278277   Italy
Saline
   University of Utah
      2005   Phase 1   NCT00346853   United States
SAR422459
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2018   Phase 1;Phase 2   EUCTR2010-023111-34-IT   France;Italy;Netherlands;United States
   Sanofi
      2011   Phase 1/Phase 2   NCT01367444   France;United States
   sanofi-aventis recherche et développement
      2016   -   EUCTR2010-023111-34-NL   France;Italy;Netherlands;United States
      2012   Phase 1;Phase 2   EUCTR2012-001990-95-FR   France;United States
SB-007
   Splice Bio
      2025   Phase 1/Phase 2   NCT06942572   United States
Sham
   Astellas Pharma Global Development, Inc.
      2018   Phase 2   NCT03364153   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
Soraprazan
   Katairo GmbH
      2019   Phase 2   EUCTR2018-001496-20-NL   Germany;Netherlands;United Kingdom
      2019   Phase 2   EUCTR2018-001496-20-IT   Germany;Italy;Netherlands;United Kingdom
      2019   Phase 2   EUCTR2018-001496-20-GB   Netherlands;United Kingdom
      2019   Phase 2   EUCTR2018-001496-20-DE   Germany;Netherlands;United Kingdom
SPVN06
   SparingVision
      2023   Phase 1/Phase 2   NCT05748873   France;United States
Standard OF care sildenafil
   Columbia University
      2014   Phase 2   NCT04356716   United States
Stargen
   Oxford BioMedica (UK) Ltd
      2011   Phase 1;Phase 2   EUCTR2010-023111-34-FR   France;Italy;Netherlands
Stem/progenitor cells transplantation
   Pomeranian Medical University Szczecin
      2018   Phase 1   NCT03772938   Poland
STG-001
   Stargazer Pharmaceuticals, Inc.
      2020   Phase 2   NCT04489511   United States
Tinlarebant
   Belite Bio, Inc
      2024   Phase 2/Phase 3   NCT06388083   Japan;United Kingdom;United States
      2022   Phase 3   NCT05244304   Australia;Belgium;China;France;Germany;Hong Kong;Netherlands;Switzerland;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-003253-36-DE   Australia;Belgium;China;France;Germany;Hong Kong;Korea, Republic of;Netherlands;Switzerland;Taiwan;United Kingdom;United States
      -   Phase 3   EUCTR2021-003253-36-FR   Australia;Belgium;China;France;Germany;Hong Kong;Switzerland;Taiwan;United Kingdom;United States
   Mata Nathan
      2024   -   JPRN-jRCT2031240209   Japan;United Kingdom;United States
   RBP4 Pty Ltd
      2021   Phase 1/Phase 2   NCT05266014   Australia;Taiwan
Vett lentiviral CON gene ABCA4
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2018   Phase 1;Phase 2   EUCTR2010-023111-34-IT   France;Italy;Netherlands;United States
Zimura
   IVERIC bio
      2018   Phase 2   EUCTR2017-004783-35-HU   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004783-35-GB   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004783-35-DE   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
   IVERIC bio, Inc.
      2018   Phase 2   EUCTR2017-004783-35-IT   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
   OPHTHOTECH CORPORATION
      2018   Phase 2   EUCTR2017-004783-35-ES   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States